
Celadon Pharmaceuticals Plc – LSE:CEL.L
Celadon Pharmaceuticals stock price today
Celadon Pharmaceuticals stock price monthly change
Celadon Pharmaceuticals stock price quarterly change
Celadon Pharmaceuticals stock price yearly change
Celadon Pharmaceuticals key metrics
Market Cap | 12.30M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.17 |
Revenue | 112.5K |
EBITDA | -8.59M |
Income | -10.71M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -7641.78% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCeladon Pharmaceuticals stock price history
Celadon Pharmaceuticals stock forecast
Celadon Pharmaceuticals financial statements
Mar 2023 | 4K | -2.15M | -53762.5% |
---|---|---|---|
Jun 2023 | 8K | -4.30M | -53762.5% |
Sep 2023 | 33.5K | -1.41M | -4237.31% |
Dec 2023 | 67K | -2.83M | -4237.31% |
Mar 2023 | 9460000 | 6.42M | 67.93% |
---|---|---|---|
Jun 2023 | 9460000 | 6.42M | 67.93% |
Sep 2023 | 9221000 | 6.04M | 65.5% |
Dec 2023 | 9221000 | 6.04M | 65.5% |
Mar 2023 | -1.49M | -104K | -124K |
---|---|---|---|
Jun 2023 | -2.97M | -208K | -264K |
Sep 2023 | -1.48M | -66.5K | 1.37M |
Dec 2023 | -2.96M | -133K | 2.74M |
Celadon Pharmaceuticals alternative data
Aug 2023 | 24 |
---|---|
Sep 2023 | 24 |
Oct 2023 | 24 |
Nov 2023 | 24 |
Dec 2023 | 24 |
Jan 2024 | 24 |
Feb 2024 | 24 |
Mar 2024 | 24 |
Apr 2024 | 24 |
May 2024 | 24 |
Jun 2024 | 24 |
Jul 2024 | 27 |
Celadon Pharmaceuticals other data
-
What's the price of Celadon Pharmaceuticals stock today?
One share of Celadon Pharmaceuticals stock can currently be purchased for approximately $80.5.
-
When is Celadon Pharmaceuticals's next earnings date?
Unfortunately, Celadon Pharmaceuticals's (CEL.L) next earnings date is currently unknown.
-
Does Celadon Pharmaceuticals pay dividends?
No, Celadon Pharmaceuticals does not pay dividends.
-
How much money does Celadon Pharmaceuticals make?
Celadon Pharmaceuticals has a market capitalization of 12.30M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 212.5% to 75K US dollars.
-
What is Celadon Pharmaceuticals's stock symbol?
Celadon Pharmaceuticals Plc is traded on the LSE under the ticker symbol "CEL.L".
-
What is Celadon Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Celadon Pharmaceuticals?
Shares of Celadon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Celadon Pharmaceuticals have?
As Jul 2024, Celadon Pharmaceuticals employs 27 workers, which is 13% more then previous month and 13% more then previous quarter.
-
When Celadon Pharmaceuticals went public?
Celadon Pharmaceuticals Plc is publicly traded company for more then 3 years since IPO on 31 Mar 2022.
-
What is Celadon Pharmaceuticals's official website?
The official website for Celadon Pharmaceuticals is celadonpharma.co.uk.
-
How can i contact Celadon Pharmaceuticals?
Celadon Pharmaceuticals can be reached via phone at +44 20 3150 0252.
Celadon Pharmaceuticals company profile:

Celadon Pharmaceuticals Plc
celadonpharma.co.ukLSE
27
Drug Manufacturers - Specialty & Generic
Healthcare
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.
London, EC1M 6DF
:
ISIN: GB00BDQYGP38
: